Roche CEO Worried About U.K. Drug Research Following Brexit

  • Schwan says patient access to medicines spurs innovation
  • Brexit may also be opportunity to redesign U.K. approach

Severin Schwan.

Photographer: Scott Eells/Bloomberg

The U.K.’s decision to leave the European Union poses a threat to research and development in the pharmaceutical industry, Roche Holding AG Chief Executive Officer Severin Schwan said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.